Telomerase activity in candidate stem cells from fetal liver and adult bone marrow - PubMed (original) (raw)

. 1998 May 1;91(9):3255-62.

Affiliations

• PMID: 9558381

Free article

Telomerase activity in candidate stem cells from fetal liver and adult bone marrow

J Yui et al. Blood. 1998.

Free article

Abstract

Telomerase is a ribonucleoprotein polymerase that synthesizes telomeric repeats onto the 3' ends of eukaryotic chromosomes. Activation of telomerase may prevent telomeric shortening and correlates with cell immortality in the germline and certain tumor cells. Candidate hematopoietic stem cells (HSC) from adult bone marrow express low levels of telomerase, which is upregulated with proliferation and/or differentiation. To address this issue, we stimulated purified candidate HSC from human adult bone marrow with stem cell factor (SCF), interleukin-3 (IL-3), and Flt3-ligand (FL). After 5 days in culture, activity was detected in total cell extracts from IL-3-, SCF + FL-, SCF + IL-3-, FL + IL-3-, and SCF + IL-3 + FL-stimulated cultures, but not from cells cultured in SCF or FL alone. Within the CD34(+) fraction of the cultured cells, significant activity was found in the CD34(+)CD71(+) fraction. In addition, PKH26 staining confirmed that detectable telomerase activity was present in dividing PKH26(lo) cells, whereas nondividing PKH26(hi) cells were telomerase negative. Because in these experiments no distinction could be made between cycling "candidate" stem cells that had retained or had lost self-renewal properties, fetal liver cells with a CD34(+)CD38(-) phenotype, highly enriched for cycling stem cells, were also examined and found to express readily detectable levels of telomerase activity. Given the replication-dependent loss of telomeric DNA in hematopoietic cells, these observations suggest that the observed telomerase activity in candidate stem cells is either expressed in a minor subset of stem cells or, more likely, is not sufficient to prevent telomere shortening.

PubMed Disclaimer

Similar articles

• Expression of Flt3 and c-kit during growth and maturation of human CD34+CD38- cells.
  Xiao M, Oppenlander BK, Plunkett JM, Dooley DC. Xiao M, et al. Exp Hematol. 1999 May;27(5):916-27. doi: 10.1016/s0301-472x(99)00020-x. Exp Hematol. 1999. PMID: 10340408
• Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors.
  Muench MO, Humeau L, Paek B, Ohkubo T, Lanier LL, Albanese CT, Bárcena A. Muench MO, et al. Exp Hematol. 2000 Aug;28(8):961-73. doi: 10.1016/s0301-472x(00)00490-2. Exp Hematol. 2000. PMID: 10989197
• Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34(+)CD38(low/neg) human bone marrow cells.
  Bennaceur-Griscelli A, Tourino C, Izac B, Vainchenker W, Coulombel L. Bennaceur-Griscelli A, et al. Blood. 1999 Jul 15;94(2):529-38. Blood. 1999. PMID: 10397720
• FLT3 ligand preserves the uncommitted CD34+CD38- progenitor cells during cytokine prestimulation for retroviral transduction.
  Nielsen SD, Husemoen LL, Sørensen TU, Gram GJ, Hansen JE. Nielsen SD, et al. J Hematother Stem Cell Res. 2000 Oct;9(5):695-701. doi: 10.1089/15258160050196731. J Hematother Stem Cell Res. 2000. PMID: 11091493

Cited by

• Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation.
  Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, de Pater E, van der Linden R, Marks-Bluth J, van der Sloot A, van den Hout M, Yokomizo T, van Schaick-Solernó ML, Delwel R, Pimanda JE, van IJcken WF, Dzierzak E. Solaimani Kartalaei P, et al. J Exp Med. 2015 Jan 12;212(1):93-106. doi: 10.1084/jem.20140767. Epub 2014 Dec 29. J Exp Med. 2015. PMID: 25547674 Free PMC article.
• The Importance of Telomere Shortening for Atherosclerosis and Mortality.
  Herrmann W, Herrmann M. Herrmann W, et al. J Cardiovasc Dev Dis. 2020 Aug 6;7(3):29. doi: 10.3390/jcdd7030029. J Cardiovasc Dev Dis. 2020. PMID: 32781553 Free PMC article. Review.
• Making the most of a little: dosage effects in eukaryotic telomere length maintenance.
  Harrington L. Harrington L. Chromosome Res. 2005;13(5):493-504. doi: 10.1007/s10577-005-0994-5. Chromosome Res. 2005. PMID: 16132814 Review.
• The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes.
  M'kacher R, Cuceu C, Al Jawhari M, Morat L, Frenzel M, Shim G, Lenain A, Hempel WM, Junker S, Girinsky T, Colicchio B, Dieterlen A, Heidingsfelder L, Borie C, Oudrhiri N, Bennaceur-Griscelli A, Moralès O, Renaud S, Van de Wyngaert Z, Jeandidier E, Delhem N, Carde P. M'kacher R, et al. Cancers (Basel). 2018 May 30;10(6):169. doi: 10.3390/cancers10060169. Cancers (Basel). 2018. PMID: 29848986 Free PMC article.
• Stem cell aging: survival of the laziest?
  Muller-Sieburg C, Sieburg HB. Muller-Sieburg C, et al. Cell Cycle. 2008 Dec 15;7(24):3798-804. doi: 10.4161/cc.7.24.7214. Epub 2008 Dec 16. Cell Cycle. 2008. PMID: 19066464 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal